Immunization

A COVID-19 booster dose increased both maternal and cord blood binding and neutralizing antibody levels against virus strains, including Omicron BA.1.

Pharmacies brace for a double wave of DIR fees while paddling against profit struggles. Enter Pharmacy AI: a transformative vehicle to navigate stormy waters, enhance efficiency, and prioritize patient care.

Gretchen Garofoli, PharmD, an associate professor at the West Virginia School of Pharmacy, discusses the current recommendations for COVID-19, respiratory syncytial virus (RSV), and influenza vaccines and vaccine hesitancy.

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

A bit of preparation can set children up for success and reduce the stress of this busy time.

Compared to the BNT162b2 vaccine, the mRNA-1273 vaccine was associated with a lower risk of adverse events, which investigators speculate was due to interrelated safety and efficacy.

CDC Advisory Committee on Immunization Practices voted 10 to 0 to recommend the routine use of nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.

Ervebo was found to be 100% effective after vaccination in preventing the onset of Ebola virus symptoms after more than 10 days.

Study shows maternal vaccination with Pfizer’s hexavalent capsular polysaccharide conjugate vaccine may protect infants against Group B Streptococcus.

If approved, the V116 vaccine would be the first pneumococcal conjugate vaccine specifically designed for adults.

Community-based pharmacy services are reaching new heights as pharmacists and pharmacy technicians are able to have a larger impact on patient care than ever before.

The prolonged lack of viral exposure has likely increased the pool of children and adults vulnerable to respiratory syncytial virus, but questions remain.

With the end of the national public health emergency for COVID-19 in May 2023, what can be expected as we look ahead to the 2023-2024 influenza season and beyond?

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

Every pharmacist can make a difference in patients’ lives by taking the time to understand and fulfill the community’s social and cultural needs.

A cancer vaccine has shown efficacy in dogs, with implications for benefit in humans.

The effectiveness of influenza vaccines varies each season and is determined by the circulating influenza virus subtype(s) and the extent to which there is an antigenic match in the vaccines to the circulating virus subtypes.

Expanding pharmacist–patient care services to include vaccine promotion and administration within ambulatory clinics is an example of the expanding role of pharmacists and their contribution to primary care practice.

Older adults are vulnerable to severe influenza-associated complications and risks, but influenza vaccines may be less effective in this population.

Investigators urge policymakers to establish flexible models that maximize coverage when respiratory syncytial virus activity is high and minimize unnecessary doses when viral activity is low.

mRNA-1345 is a vaccine indicated for the prevention of respiratory syncytial virus-associated lower respiratory tract disease and acute respiratory disease.

Less than half of respondents would recommend a vaccine against respiratory syncytial virus to a pregnant friend or family member.

The new RSV vaccines are expected to be available in fall 2023.

Independent pharmacies can provide more personalized care to individuals with behavioral health conditions or intellectual and developmental disabilities.

As the COVID-19 Public Health Emergency and PREP Act Expansions end, the ability of technicians to immunize patients in the future remains unclear.

CDC Advisory Committee on Immunization Practices recommends the use of respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy) for adults 60 years of age and older based on findings from the first season of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial.

Novavax announced the development of a protein-based monovalent XBB COVID-19 vaccine with the intention of it being manufactured and available for the fall vaccination campaign.

A single dose of Arexvy was found effective preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older across 2 full RSV seasons.

Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.

Adult and maternal RSV vaccines reveal positive findings.